News
Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback